Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure

The study is designed as a retrospective cohort analysis of patients with chronic heart failure who attended the outpatient heart failure clinics at University Medical Centre Ljubljana between January 1, 2019, and December 31, 2023. Patients will be divided into two groups: those who initiated SGLT2 inhibitor therapy (empagliflozin or dapagliflozin 10 mg daily) and a control group of comparable patients receiving guideline-directed medical therapy without SGLT2 inhibitors. Data will be extracted from electronic medical records at baseline, 6 months, and 12 months. The primary focus is on changes in erythropoietic parameters (hemoglobin, hematocrit, red blood cell count, red cell distribution width) and their association with changes in cardiac function (LVEF, NTproBNP, NYHA class) and renal function (eGFR, serum creatinine).

Inclusion criteria

• Diagnosis of chronic heart failure
• Receiving guideline-directed medical therapy for heart failure for at least 3 months prior to inclusion
• Age ≥18 years

Exclusion criteria

• Incomplete or missing data in electronic medical records
• Acute cardiac event within 3 months prior to baseline
• Active malignancy or hematological disease affecting erythropoiesis
• Use of erythropoiesis-stimulating agents or regular erythrocyte transfusions during the observation period
• Severe renal insufficiency (eGFR <15 mL/min/1.73m²)
• Severe liver insufficiency (AST/ALT >3× upper limit of normal, bilirubin >2× upper limit of normal)
• Known allergy to any SGLT2 inhibitor component
• Pregnancy or breastfeeding